Patents by Inventor Stephane D'Aoust

Stephane D'Aoust has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12358873
    Abstract: Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.
    Type: Grant
    Filed: February 29, 2024
    Date of Patent: July 15, 2025
    Assignee: Canna-Chemistries LLC
    Inventors: Nate Schultheiss, Travis Lee Houston, Stephan D. Parent
  • Patent number: 12351588
    Abstract: Disclosed herein are salt and solvate forms of. (1S,3?R,6?R,7?S,8?E,11?S,12?R)-6-chloro-7?-methoxy-11?,12?-dimethyl-3,4-dihydro-2H,15?H-spiro[naphthalene-1,22?-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15?-one 13?,13?-dioxide (AMG 176): such as crystalline salt and solvate forms thereof. Also disclosed are methods of making the salt and solvate forms, and methods of treating diseases and disorders with the salt and solvate forms.
    Type: Grant
    Filed: April 5, 2023
    Date of Patent: July 8, 2025
    Assignee: AMGEN INC.
    Inventors: Henry Morrison, Jason S. Tedrow, Stephan D. Parent, Courtney Johnson, Travis Houston, Melanie Bevill
  • Publication number: 20250179062
    Abstract: The present disclosure provides crystalline forms of the compound having formula (I): (I), wherein the crystalline forms are crystalline Forms A, B, C, E, F, and H, each of which is characterized by an X-ray powder diffraction (XRPD) pattern. The present disclosure also provides methods for preparing crystalline forms, in particular Form A. The present disclosure further provides methods of treating various skin disorders using the crystalline forms of the disclosure or a pharmaceutical composition thereof.
    Type: Application
    Filed: January 20, 2022
    Publication date: June 5, 2025
    Inventors: Stephan D. PARENT, Courtney S. JOHNSON, John KINCAID
  • Patent number: 12312359
    Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: May 27, 2025
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
  • Patent number: 12252486
    Abstract: The present invention provides a crystalline form and stable salts of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several hydrochloride salt forms, phosphate salt form, mesylate salt form, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: March 18, 2025
    Assignee: Amgen Inc.
    Inventors: Mary Chaves, Ron C. Kelly, Prashant Agarwal, Stephan D. Parent, Darren Leonard Reid, Roman Shimanovich
  • Publication number: 20250073244
    Abstract: The present invention provides crystalline forms of a pentaaza macrocyclic ring complex according to the following formula: Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of disease states.
    Type: Application
    Filed: March 7, 2024
    Publication date: March 6, 2025
    Inventors: Jeffrey A. SCHOLTEN, Stephan D. PARENT, Yike SI, Tianjing ZHAO, Xiaoyang WANG, Travis L. HOUSTON
  • Publication number: 20250032471
    Abstract: Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
    Type: Application
    Filed: October 10, 2024
    Publication date: January 30, 2025
    Inventors: Zhe LI, Stephan D. PARENT, Travis HOUSTON
  • Publication number: 20250011006
    Abstract: The invention(s) include embodiments and applications of: a system for package handling, the system including: an aerial vehicle and a conveying subsystem configured to interface with the aerial vehicle. The system can execute operation modes, associated with loading and unloading of multiple packages, and delivering one or more packages to receiving sites.
    Type: Application
    Filed: July 7, 2024
    Publication date: January 9, 2025
    Inventors: Manal Habib, Ian Fernandez, Brendan Michael Szuwalski, Stephane D'Urso, Petr Ptacek
  • Publication number: 20240300988
    Abstract: The present disclosure provides polymorph forms of pentaaza macrocyclic ring Also provided are pharmaceutical compositions that include the provided polymorph forms and methods of using the provided polymorph forms and pharmaceutical compositions for the treatment of disease states.
    Type: Application
    Filed: March 7, 2024
    Publication date: September 12, 2024
    Inventors: Stephan D. PARENT, Tanise SHATTOCK-GORDON
  • Publication number: 20240300897
    Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Application
    Filed: May 7, 2024
    Publication date: September 12, 2024
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • Publication number: 20240269118
    Abstract: The present disclosure is related to a polymorphic form of ritonavir prepared by novel methods that require less time to produce the polymorphic form, the methods of preparing the polymorphic form, pharmaceutical compositions comprising the polymorphic form produced by the provided methods, and corresponding methods of treatment with the polymorphic form produced by the provided methods.
    Type: Application
    Filed: March 29, 2024
    Publication date: August 15, 2024
    Inventors: Adrian RADOCEA, Jordan Michael CROOM, Larry Robin CHAN, Ami Sanat BHAVSAR, Pamela A. SMITH, Stephen R. BYRN, Stephan D. PARENT, Dale K. PURCELL
  • Publication number: 20240246912
    Abstract: Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.
    Type: Application
    Filed: February 29, 2024
    Publication date: July 25, 2024
    Inventors: Nate Schultheiss, Travis Lee Houston, Stephan D. Parent
  • Patent number: 12027843
    Abstract: Systems, methods, and computer-readable media are disclosed for high-speed falling conductor protection in electric distribution systems. An example method may include calculating, by a processor, at a first time, and for each phase, one or more first impedance values associated with one or more terminals of a transmission line. The example method may also include calculating, by the processor, at a second time, and for each phase, one or more second impedance values associated with the one or more terminals. The example method may also include determining, by the processor, that a rate of change of an impedance of the one or more terminals is greater than a threshold rate of change. The example method may also include determining, by the processor and based on the determination that the rate of change of the one or more terminals is greater than the threshold rate of change, that the transmission line has broken.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: July 2, 2024
    Assignee: GE Infrastructure Technology LLC
    Inventors: Hasan Bayat, Johannes Kruger, Yujie Yin, Mohammad Amin Zamani, Stéphan D. Picard
  • Patent number: 12017995
    Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: June 25, 2024
    Assignee: Exelixis, Inc.
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • Publication number: 20240076290
    Abstract: Forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), or salts or solvates thereof, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
    Type: Application
    Filed: November 1, 2023
    Publication date: March 7, 2024
    Inventors: STEPHAN D. PARENT, TRAVIS LEE HOUSTON, COURTNEY S. JOHNSON, FANG WANG
  • Patent number: 11851424
    Abstract: Forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), or salts or solvates thereof, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: December 26, 2023
    Assignee: GLOBAL BLOOD THERAPEUTICS, INC.
    Inventors: Stephan D. Parent, Travis Lee Houston, Courtney S. Johnson, Fang Wang
  • Patent number: 11844768
    Abstract: Nordihydroguaiaretic acid (NDGA) derivatives, including terameprocol (TMP) have utility as anti-viral agents for use on patients infected with or at risk of infection with a coronavirus, including SARS-CoV-2. In vitro studies show coronavirus-infected cells treated with 0.2 ?M-20 ?M TMP show reduced viral RNA activity in vitro. Treatment-related cytotoxicity is not shown at 0.2 ?M TMP with a low percentage of cytotoxicity shown at 5 ?M TMP. In application, the NDGA derivatives may be administered to a patient intravenously at a molar concentration of 0.1-50 ?M or orally at a molar concentration of 0.1-100 ?M.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: December 19, 2023
    Assignee: Erimos Pharmaceuticals, LLC
    Inventors: Jeffrey Khoo, Stephan D. Glenn
  • Publication number: 20230365619
    Abstract: Crystalline forms of crystalline sodium cholesteryl sulfate are disclosed herein. Such forms include crystalline sodium cholesteryl sulfate Form B, crystalline sodium cholesteryl sulfate Form F, crystalline sodium cholesteryl sulfate Form H, crystalline sodium cholesteryl sulfate Form J, crystalline sodium cholesteryl sulfate Form K, crystalline sodium cholesteryl sulfate Form L, crystalline sodium cholesteryl sulfate Form M, and crystalline sodium cholesteryl sulfate Form N. Processes for making such crystalline forms and methods of treating disease with form are further provided.
    Type: Application
    Filed: October 11, 2021
    Publication date: November 16, 2023
    Inventors: WEIQI LIN, STEPHAN D. PARENT, COURTNEY S. JOHNSON
  • Publication number: 20230365618
    Abstract: Crystalline forms of thiocholesterol are disclosed herein. Such forms include crystalline Form thiocholesterol, crystalline Form B thiocholesterol, crystalline thiocholesterol Form C. Processes for making crystalline thiocholesterol, pharmaceutical compositions comprising crystalline thiocholesterol, methods of treatment comprising administering crystalline thiocholesterol, including ctystalline thiocholesterol Form A, crystalline thiocholesterol Form B, and/or crystalline thiocholesterol Form C are further provided.
    Type: Application
    Filed: October 11, 2021
    Publication date: November 16, 2023
    Inventors: ANDREW R. MIKSZTAL, WEIQI LIN, MICHAEL HOLTZ-MULHOLLAND, JULIETTE SABBATANI, TRAVIS LEE HOUSTON, STEPHAN D. PARENT
  • Publication number: 20230312602
    Abstract: Disclosed herein are salt and solvate forms of. (1S,3?R,6?R,7?S,8?E,11?S,12?R)-6-chloro-7?-methoxy-11?,12?-dimethyl-3,4-dihydro-2H,15?H-spiro[naphthalene-1,22?-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15?-one 13?,13?-dioxide (AMG 176): such as crystalline salt and solvate forms thereof. Also disclosed are methods of making the salt and solvate forms, and methods of treating diseases and disorders with the salt and solvate forms.
    Type: Application
    Filed: April 5, 2023
    Publication date: October 5, 2023
    Inventors: Henry Morrison, Jason S. Tedrow, Stephan D. Parent, Courtney Johnson, Travis Houston, Melanie Bevill